Artesunate

[{"orgOrder":0,"company":"Frantz Viral Therapeutics","sponsor":"Amarex Clinical Research | University of California, San Francisco | Anal Dysplasia Clinic MidWest | Laser Surgery Care","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Frantz Viral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Frantz Viral Therapeutics \/ Amarex Clinical Research | University of California, San Francisco | Anal Dysplasia Clinic MidWest | Laser Surgery Care","highestDevelopmentStatusID":"8","companyTruncated":"Frantz Viral Therapeutics \/ Amarex Clinical Research | University of California, San Francisco | Anal Dysplasia Clinic MidWest | Laser Surgery Care"},{"orgOrder":0,"company":"Frantz Viral Therapeutics","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Frantz Viral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Frantz Viral Therapeutics \/ Cleveland Clinic","highestDevelopmentStatusID":"8","companyTruncated":"Frantz Viral Therapeutics \/ Cleveland Clinic"},{"orgOrder":0,"company":"Frantz Viral Therapeutics","sponsor":"Laser Surgery Care | Anal Dysplasia Clinic MidWest","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Frantz Viral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Frantz Viral Therapeutics \/ Laser Surgery Care | Anal Dysplasia Clinic MidWest","highestDevelopmentStatusID":"8","companyTruncated":"Frantz Viral Therapeutics \/ Laser Surgery Care | Anal Dysplasia Clinic MidWest"},{"orgOrder":0,"company":"Amivas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Amivas","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amivas \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amivas \/ Inapplicable"},{"orgOrder":0,"company":"Amivas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Amivas","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amivas \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amivas \/ Inapplicable"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shin Poong Pharm Co Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"10","companyTruncated":"Shin Poong Pharm Co Ltd \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shin Poong Pharm Co Ltd \/ Inapplicable"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Oncology","graph2":"Phase I","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Vaginal Pessary","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ Gilead Sciences"},{"orgOrder":0,"company":"Mangalam Drugs & Organics Ltd","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Pyronaridine Tetraphosphate","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mangalam Drugs & Organics Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mangalam Drugs & Organics Ltd \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"15","companyTruncated":"Mangalam Drugs & Organics Ltd \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Ministry of Public Health, DRC","sponsor":"University of Kinshasa | World Health Organization | Institut National de Recherche Biom\u00e9dicale","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Ministry of Public Health, DRC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ministry of Public Health, DRC \/ University of Kinshasa | World Health Organization | Institut National de Recherche Biom\u00e9dicale","highestDevelopmentStatusID":"11","companyTruncated":"Ministry of Public Health, DRC \/ University of Kinshasa | World Health Organization | Institut National de Recherche Biom\u00e9dicale"},{"orgOrder":0,"company":"Nepal Health Research Council","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Nepal Health Research Council","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nepal Health Research Council \/ World Health Organization","highestDevelopmentStatusID":"11","companyTruncated":"Nepal Health Research Council \/ World Health Organization"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"AbbVie Inc | Apotex Inc | World Health Organization | University of British Columbia | Arch Biopartners","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ AbbVie Inc | Apotex Inc | World Health Organization | University of British Columbia | Arch Biopartners","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ AbbVie Inc | Apotex Inc | World Health Organization | University of British Columbia | Arch Biopartners"},{"orgOrder":0,"company":"University of Kinshasa","sponsor":"European & Developing Countries Clinical Trials Partnership | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Kinshasa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Kinshasa \/ European & Developing Countries Clinical Trials Partnership | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"University of Kinshasa \/ European & Developing Countries Clinical Trials Partnership | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Amivas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amivas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amivas \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amivas \/ Inapplicable"},{"orgOrder":0,"company":"Metanoic Health Ltd.","sponsor":"Clinical Research Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Artesunate","moa":"ATP2A1 | SERCA2","graph1":"Oncology","graph2":"Phase II","graph3":"Metanoic Health Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metanoic Health Ltd. \/ Clinical Research Malaysia","highestDevelopmentStatusID":"8","companyTruncated":"Metanoic Health Ltd. \/ Clinical Research Malaysia"},{"orgOrder":0,"company":"Metanoic Health Ltd.","sponsor":"Clinical Research Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Artesunate","moa":"ATP2A1 | SERCA2","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Metanoic Health Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metanoic Health Ltd. \/ Clinical Research Malaysia","highestDevelopmentStatusID":"8","companyTruncated":"Metanoic Health Ltd. \/ Clinical Research Malaysia"}]